Gaston De Serres
- Formation
- à venir
Aucune offre active
Autres opportunités de carrière
- Axe principal
- Santé des populations et environnementale
- Adresse
- 2400, avenue d'Estimauville, 3e étage
Québec (Québec)
CANADA G1E 7G9 - Téléphone
- +1 418-666-7000, poste 274
- Télécopieur
- +1 418-666-2776
- Courriel
- Gaston.DeSerres@ssss.gouv.qc.ca
Publications récentes (voir toutes les publications de ce chercheur)
Skowronski D, De Serres G, Janjua N, Gardy J, Gilca V, Dionne M, Hamelin M, Rheaume C, Boivin G. Cross-reactive antibody to swine influenza A(H3N2) subtype virus in children and adults before and after immunisation with 2010/11 trivalent inactivated influenza vaccine in Canada, August to November 2010. Euro surveillance : bulletin europeen sur les maladies transmissibles = European communicable disease bulletin,
2012. 17:
Halperin SA, Scheifele D, De Serres G, Noya F, Meekison W, Zickler P, Larrivee L, Langley JM, McNeil SA, Dobson S, Jordanov E, Thakur M, Decker MD, Johnson DR. Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine,
2012. 30: 974-82
Skowronski DM, Janjua NZ, Sonfack Tsafack EP, Ouakki M, Hoang L, De Serres G. The number needed to vaccinate to prevent infant pertussis hospitalization and death through parent cocoon immunization. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
2012. 54: 318-27
Papenburg J, Carbonneau J, Hamelin ME, Isabel S, Bouhy X, Ohoumanne N, Dery P, Paes BA, Corbeil J, Bergeron MG, De Serres G, Boivin G. Molecular evolution of respiratory syncytial virus fusion gene, Canada, 2006-2010. Emerging infectious diseases,
2012. 18: 120-4
Gilca V, De Serres G, Hamelin ME, Boivin G, Ouakki M, Boulianne N, Sauvageau C, Dionne M, Gilca R, Skowronski D. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine,
2011. 30: 35-41
Papenburg J, Baz M, Hamelin ME, Rheaume C, Carbonneau J, Ouakki M, Rouleau I, De Serres G, Boivin G. Evaluation of serological diagnostic methods for the 2009 pandemic influenza A (H1N1) virus. Clinical and vaccine immunology : CVI,
2011. 18: 520-2
Skowronski DM, Hottes TS, Chong M, De Serres G, Scheifele DW, Ward BJ, Halperin SA, Janjua NZ, Chan T, Sabaiduc S, Petric M. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics,
2011. 128: e276-89
Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, Crowcroft N, Kwindt TL, Tang P, Charest H, Fonseca K, Gubbay JB, Bastien N, Li Y, Petric M. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ (Clinical research ed.),
2011. 342: c7297
Skowronski DM, Hottes TS, McElhaney JE, Janjua NZ, Sabaiduc S, Chan T, Gentleman B, Purych D, Gardy J, Patrick DM, Brunham RC, De Serres G, Petric M. Immuno-epidemiologic Correlates of Pandemic H1N1 Surveillance Observations: Higher Antibody and Lower Cell-Mediated Immune Responses with Advanced Age. The Journal of infectious diseases,
2011. 203: 158-67
De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. The Pediatric infectious disease journal,
2011. 30: 566-9
